Who are the PLWH who might refuse to participate in HIV cure-related clinical trials with treatment interruption?

Christel Protière (1, 2) , Marion Fiorentino (2, 1) , Abdourahmane Sow (2, 1) , Marie Préau (3) , Marion Mora (2) , Lisa Fressard (4, 1, 5) , Laurence Meyer (6) , Jean-Daniel Lelièvre (7) , Olivier Lambotte (8) , Bruno Spire (9, 2) , Marie Suzan-Monti (2)

1 ORS PACA - Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille]
2 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
3 GRePS - Groupe de Recherche en Psychologie Sociale
4 VITROME - Vecteurs - Infections tropicales et méditerranéennes
5 IHU Marseille - Institut Hospitalier Universitaire Méditerranée Infection
6 CESP - INSERM U1018 - Equipe 7 - Sexualité et soins (Genre, Sexualité, Santé)
7 UPEC Médecine - Université Paris-Est Créteil Val-de-Marne - Faculté de médecine
8 Immunologie antivirale systémique et cérébrale
9 ORS PACA

Achieving a HIV cure has become a research priority. As any improvement of knowledge, which could help scientists design new HIV cure-related clinical trials (HCRCT) depends on the risks potential participants are willing to accept, it is important to understand who will agree or refuse to participate and in which proportions. By providing insights into factors associated with reluctance toward HCRCT participation, our results may help clinicians in patient recruitment.

Domains: Life Sciences [q-bio]; Microbiology and Parasitology; Bacteriology; Life Sciences [q-bio]; Microbiology and Parasitology; Virology; Life Sciences [q-bio]; Microbiology and Parasitology; Parasitology; Life Sciences [q-bio]; Human health and pathology; Cardiology and cardiovascular system; Life Sciences [q-bio]; Human health and pathology; Emerging diseases; Life Sciences [q-bio]; Human health and pathology; Infectious diseases

Christel Protière, Marion Fiorentino, Abdourahmane Sow, Marie Préau, Marion Mora, et al.. Who are the PLWH who might refuse to participate in HIV cure-related clinical trials with treatment interruption?. AIDS, 2020, pp.1. ⟨10.1097/QAD.0000000000002530⟩. ⟨hal-02547988⟩